Zweegman S, Schjesvold FH, Van der Holt B, et al. Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/Nmsg 21#13 Trial. ASH Annual Meeting and Exposition 2018, abstract 800.
Aanpassing sluiscriteria voor nieuwe dure geneesmiddelen
jan 2023 | Borstkanker, Dermato-oncologie, Gynaecologische oncologie, Immuuntherapie, Leukemie, Longoncologie, Lymfoom, Maag-darm-leveroncologie, MM, Uro-oncologie